AUTHORS
Amer M. Zeidan, MD, Maher Abdul-Hay, MD2, Huafeng Wang, MD3, Hun Chuah4, Qian Jiang Jr, MD5, Joshua F. Zeidner, MD6, Zhichao Chen, MD7, Guru Subramanian Guru Murthy, MD8, Rami Komrokji, MD9, Xingli Zhao, MD10, Xudong Wei, MD, PhD11, Keith Fay12, Aijun Liao, MD, PhD13, Jianyu Weng, MD, PhD14, Shaun Fleming15, Kate Ma16, Haowen Xu17, Weige Wang, MD, PhD18, Renbin Zhao, PhD19, Jie Jin, MD20
AFFILIATIONS
1 Yale School of Medicine, New Haven, Connecticut, United States
2 NYU Langone Health‘s Perlmutter Cancer Center, New York, United States
3 The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
4 Royal Perth Hospital, Perth, Australia
5 Peking University People’s Hospital, Beijing, China
6 University of North Carolina,Lineberger Comprehensive Cancer Center, Chapel Hill, United States
7 Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
8 Medical College of Wisconsin, Milwaukee, United States
9 Moffitt Cancer Center, Tampa, United States
10 Oncology Center, Tianjin People‘s Hospital, Tianjin, China
11 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
12 St Vincent‘s Hospital Sydney, Sydney, Australia
13 Shengjing Hospital of China Medical University, Shenyang, China
14 Guangdong Provincial People’s Hospital of Southern Medical University, Guangzhou, China
15 Alfred Health, Melbourne, Australia
16 InnoCare Pharma Limited, Beijing, China
17 InnoCare Pharma Limited, Beijing, China
18 InnoCare Pharma Limited, Beijing, China
19 InnoCare Pharma Limited, Beijing, China
20 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Efficacy and Safety of Mesutoclax, a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Acute Myeloid Leukemia Patients Harboring TP53 Mutations or Following Failure of Prior BCL-2 Inhibitors and Hypomethylating Agents
Amer M.Zeidan1, Maher Abdul Hay2, Huafeng Wang3, Hun Chuah4, Qian Jiang5, Joshua Zeidner6, Zhichao Chen7, Guru Subramanian Guru Murthy8, Rami Komrokji9, Xingli Zhao10, Xudong Wei11, Fay Keith12, Aijun Liao13, Jianyu Weng14, Shaun Fleming15, Shuo Ma16, Haowen Xu16, Weige Wang16, Renbin Zhao16, Jie Jin3
¹ Yale School of Medicine, New Haven, United States; ² NYU Langone Health‘s Perlmutter Cancer Center, New York, United States; ³ Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; ⁴ Royal Perth Hospital, Perth, Australia; ⁵ Peking University People’s Hospital, Beijing, China; ⁶ University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, United States; ⁷ Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; ⁸ Medical College of Wisconsin, Milwaukee, United States; ⁹ Moffitt Cancer Center, Tampa, United States; ¹⁰ Oncology Center, Tianjin People‘s Hospital, Tianjin, China; ¹¹ The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; ¹² St Vincent‘s Hospital Sydney, Sydney, Australia; ¹³ Shengjing Hospital of China Medical University, Shenyang, China; ¹⁴ Guangdong Provincial People’s Hospital of Southern Medical University, Guangzhou, China; ¹⁵ Alfred Health, Melbourne, Australia; ¹⁶InnoCare Pharma Limited, Beijing, China
Background:
Venetoclax combined with hypomethylating agents (HMAs) is standard treatment for treatment-naive (TN) older or unfit patients with acute myeloid leukemia (AML). However, outcomes are dismal in relapsed or refractory (R/R) AML with prior venetoclax plus HMA therapy, and clinical benefit remains limited in TP53-mutated AML. Mesutoclax is a novel, potent, and highly selective BCL-2 inhibitor with a favorable pharmacokinetic profile that has shown promising early clinical activity in AML (J Clin Oncol 2026;44:6506).
Methods:
ICP-CL-01205 (NCT06656494) is an ongoing global phase 1 study evaluating mesutoclax (100 mg, 125 mg, or 150 mg once daily for 28 days per cycle) plus azacitidine in patients with AML. Efficacy was evaluated by 2017 European Leukemia Net (ELN) , and treatment-emergent adverse events (TEAEs) were assessed per NCI-CTCAE v5.0. Here, we report efficacy in R/R AML and TP53-mutated TN AML, and pooled safety across all AML cohorts.
Results:
As of July 13, 2026, 26 patients with R/R AML were enrolled (median age: 60 years [range: 22–86]; 50% adverse risk per 2017 ELN). 61.5% (n=16) had prior HMA therapy and Bcl-2 inhibitors (15 venetoclax, 1 lisaftoclax), and 19.2% (n=5) had prior allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Median follow up time was 3.12 months. Among 18 evaluable patients with R/R AML, the overall response rate (ORR;CR + CRi + MLFS) was 50% (9/18; comprising 4 CR, 3 CRi, and 2 MLFS). In evaluable patients with prior BCL-2 inhibitor plus HMA failure (n=10), the ORR was 60% ( 4 composite CR [cCR], and 2 MLFS).
Among 9 evaluable TN AML patients harboring TP53 mutations (including 3 bi-allelic and 4 complex karyotype), the response rate was 77.8% (7/9; 4 CR, 2 MLFS,1 PR), median DOR was 7.4 months, the MRD− rate was 33.3% per flow cytometry, and the 9-month OS rate was 62.5%.
In the pooled safety population of patients with AML (N=73) included heavily treated R/R AML, the most common (≥10%) grade ≥3 TEAEs were decreased white blood cell count (64.4%), neutropenia (64.4%), thrombocytopenia (54.8%), anemia (41.1%), infections (32.9%).,and neutropenic fever( 30.1%). Serious adverse events (SAEs) occurred in 38.4%, and TEAEs led to treatment discontinuation is 5.5%. The 30-day mortality rate was 2.7% (n=2; 1 TN AML patient died due to an accident unrelated to treatment, and 1 heavily pretreated post-HSCT patient died from sepsis).
Conclusion:
Mesutoclax in combination with azacitidine demonstrates encouraging preliminary efficacy and a manageable safety profile in patients with TP53-mutated AML or R/R AML following failure of BCL-2 inhibitor/HMA therapy. These findings highlight the potential of mesutoclax to address critical unmet medical needs unfulfilled by current venetoclax-based regimens. Both cohorts are actively enrolling, and updated data will be presented at the meeting.
DISCLOSURES
Amer M. Zeidan, MD: AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony); AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony)